24 filings · most recent first
APGE 8-K Filings
Apogee Therapeutics Announces Full Year 2025 Financial Results And Pipeline
Apogee Therapeutics Announces Election Of Directors At 2026 Annual Meeting
Apogee Therapeutics Reports Strong Q1 2026 Financial Results And Pipeline
Apogee Therapeutics Board Members Resign
Apogee Therapeutics Reports Q3 2025 Financial Results And Positive Apg333 Trial
Abbvie To Acquire Apogee Therapeutics In 109 Billion Deal
Apogee Therapeutics Enters Into Antibody Discovery And License Agreement With
Apogee Therapeutics Secures 13 Billion Strategic Financing With Blackstone Life
Apogee Therapeutics Announces Positive Phase 2 Trial Results For Zumilokibart
Apogee Therapeutics Announces Public Offering Of Common Stock
Apogee Therapeutics Announces Positive Phase 2 Trial Results For Zumilokibart
Apogee Therapeutics Announces Positive Interim Results From Phase 1B Trial Of
Apogee Therapeutics Announces 3233M Public Offering And Clinical Trial Updates
Apogee Therapeutics Announces Positive Clinical Trial Results For Apg777
Apogee Therapeutics Reports Q1 2025 Financial Results And Pipeline Updates
Apogee Therapeutics Enters Manufacturing Agreement With Samsung Biologics
Apogee Therapeutics Announces 2024 Full Year Results And Positive Phase 1 Data
Apogee Therapeutics Announces First Patient Dosed In Phase 2 Apex Trial For
Apogee Therapeutics Initiates Dosing In Phase 1 Trial For Apg333
Apogee Therapeutics Hosts Virtual Rd Day Highlights Progress Of Biologic
Apogee Therapeutics Announces Positive Phase 1 Trial Results For Apg777
Apogee Therapeutics Reports Positive Clinical Trial Results And Second Quarter
Apogee Therapeutics Announces 2025 Annual Meeting Voting Results
Apogee Therapeutics Reports Third Quarter 2024 Financial Results And Pipeline